Cannabis
Mindset Pharma to Commence Trading on the CSE on December 23, 2020 Under the Symbol “MSET”
Toronto, Ontario–(Newsfile Corp. – December 22, 2020) – Mindset Pharma Inc. (CSE: MSET) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psychedelic medicines for the treatment of neuropsychiatric and neurological indications with unmet needs, is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (“CSE“) effective at the open of business on Wednesday, December 23, 2020, under the symbol “MSET”.
James Lanthier, CEO of Mindset, commented, “I am excited to share this announcement as it represents a significant milestone for Mindset and our shareholders. Our portfolio of next-generation patent-pending drug candidates and our innovative process to efficiently synthesize pharmaceutical-grade psilocybin are unique technologies that have the potential to play a significant role in the growth of the emerging psychedelic medication market. With the proceeds from the closing of the Company’s recent private placement offering and the completion of Ontario Brain Institute investment, we are well funded to continue to advance and further develop our drug development and synthesis programs. We look forward to sharing additional updates around Mindset’s progress shortly.”
FOR MORE INFORMATION, PLEASE CONTACT:
James Lanthier
Chief Executive Officer
[email protected]
Jason Atkinson
Corporate Development
[email protected]
About Mindset Pharma
Mindset Pharma is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds.
www.mindsetpharma.com
Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, unless required by law. The reader is cautioned not to place undue reliance on forward-looking information.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70837
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis1 week ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis5 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis5 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis4 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
-
Cannabis3 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis3 days ago
Rubicon Organics Reports Q1 2024 Financial Results